Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,041 to 1,060 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. | Nat Commun | 2022 | 35538074 | PubTator, text mining | PubMed |
| Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs. | Comput Biol Med | 2022 | 35533462 | PubTator, text mining | PubMed |
| Phytomedicines explored under in vitro and in silico studies against coronavirus: An opportunity to develop traditional medicines. | S Afr J Bot | 2022 | 35530267 | PubTator, text mining | PubMed |
| Coinfection of fungi with SARS-CoV-2 is a detrimental health risk for COVID-19 patients. | Beni Suef Univ J Basic Appl Sci | 2022 | 35529527 | PubTator, text mining | PubMed |
| The Potential of Eukaryotic Cell-Free Systems as a Rapid Response to Novel Zoonotic Pathogens: Analysis of SARS-CoV-2 Viral Proteins. | Front Bioeng Biotechnol | 2022 | 35519622 | PubTator, text mining | PubMed |
| Prediction of coronavirus 3C-like protease cleavage sites using machine-learning algorithms. | Virol Sin | 2022 | 35513273 | PubTator, text mining | PubMed |
| The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy. | J Biomed Sci | 2022 | 35505345 | PubTator, text mining | PubMed |
| Prevalence and genotypes distribution of group A rotavirus among outpatient children under 5 years with acute diarrhea in Shanghai, China, 2012-2018. | BMC Gastroenterol | 2022 | 35505284 | PubTator, text mining | PubMed |
| Alterations in SARS-CoV-2 Omicron and Delta peptides presentation by HLA molecules. | PeerJ | 2022 | 35502206 | PubTator, text mining | PubMed |
| Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. | PLoS One | 2022 | 35499994 | PubTator, text mining | PubMed |
| Investigation of changes in protein stability and substrate affinity of 3CL-protease of SARS-CoV-2 caused by mutations. | Genet Mol Biol | 2022 | 35499274 | PubTator, text mining | PubMed |
| Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors. | Front Chem | 2022 | 35494659 | PubTator, text mining | PubMed |
| SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? | Vaccine | 2022 | 35484041 | PubTator, text mining | PubMed |
| Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. | Sci Transl Med | 2022 | 35482820 | PubTator, text mining | PubMed |
| A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. | Commun Biol | 2022 | 35478219 | PubTator, text mining | PubMed |
| Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease. | Nat Commun | 2022 | 35477935 | PubTator, text mining | PubMed |
| Unravelling Vitamin B12 as a potential inhibitor against SARS-CoV-2: A computational approach. | Inform Med Unlocked | 2022 | 35475214 | PubTator, text mining | PubMed |
| Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells. | mBio | 2022 | 35471084 | PubTator, text mining | PubMed |
| Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant. | J Phys Chem Lett | 2022 | 35467344 | PubTator, text mining | PubMed |
| Epitranscriptomics of SARS-CoV-2 Infection. | Front Cell Dev Biol | 2022 | 35465335 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=53